YMC026 is developed by Yuhan Corporation.

What development phase is YMC026 in?

YMC026 is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

YMC026

Yuhan Corporation · FDA-approved active Small molecule Quality 4/100

YMC026, marketed by Yuhan Corporation, is a small molecule with a specific mechanism of action, though its primary indication and revenue figures are not specified. The drug's key strength lies in its patented composition, which is protected until 2028. The primary risk is the lack of detailed clinical trial results and competitor information, which could impact its market position and strategic planning.

At a glance

Generic name	YMC026
Sponsor	Yuhan Corporation
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Clinical Trial to Evaluate the Efficacy and Safety of YMC026 in Respiratory Disease Patients (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

YMC026 CI brief — competitive landscape report
YMC026 updates RSS · CI watch RSS
Yuhan Corporation portfolio CI